Clinical and epidemiological evaluation of influenza and SARS-CoV-2 coinfected cases.

Abstract

Coinfection of COVID-19 with influenza pathogens, may complicate the diagnosis, treatment, and prognosis, which is a new concern. This study aims to evaluate COVID-19 and influenza coinfected cases during the flu season, while the SARS-CoV-2 pandemic continues. The study was conducted between November 2021 and January 2022. A total of 1987 (1752 outpatients, 235 inpatients) patients were included, and 44 simultaneous COVID-19 and influenza laboratory-confirmed diagnoses. During the study period, 1553 patients were diagnosed with COVID-19, 390 influenza, and 44 were diagnosed with coinfection. The incidence of coinfected cases was 2.2% (n = 44) in all patients, When coinfected cases were examined, there was a statistically significant difference between the disease duration in the inpatients (19.86 ± 10.78 days) and the disease duration in the outpatients (7.63 ± 2.25 days) (p < 0.05). 31.8% (n = 14) of coinfected cases were hospitalized, and the mortality rate was 50.0% (n = 7) in hospitalized patients. Coinfection with SARS-CoV-2 and İnfluenza was not uncommon. Data on coinfected cases are limited in the literature. The coinfection with SARS-CoV-2 and influenza A should be considered in patients with complaints such as fever, myalgia, weakness, shortness of breath, and cough during the flu season. Using the diagnostic test showing two diseases in a single sample may contribute to protecting patient and community health in follow-up and treatment.